Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy.

Capal JK, Franz DN.

Neuropsychiatr Dis Treat. 2016 Aug 25;12:2165-72. doi: 10.2147/NDT.S91248. eCollection 2016. Review.

2.

EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.

Fogarasi A, De Waele L, Bartalini G, Jozwiak S, Laforgia N, Verhelst H, Petrak B, Pedespan JM, Witt O, Castellana R, Crippa S, Gislimberti G, Gyorsok Z.

BMC Neurol. 2016 Aug 8;16:126. doi: 10.1186/s12883-016-0658-4.

3.

Tuberous sclerosis complex-associated renal angiomyolipomas: A single center study of 17 consecutive cases.

Wang H, Long Q, Wang Y, Liu L, Zhou L, Guo J.

Oncol Lett. 2016 Aug;12(2):1501-1506. Epub 2016 Jun 23.

4.

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.

Franz DN, Belousova E, Sparagana S, Bebin EM, Frost MD, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Niolat J, Jóźwiak S.

PLoS One. 2016 Jun 28;11(6):e0158476. doi: 10.1371/journal.pone.0158476. eCollection 2016.

5.

Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.

Hwang SK, Lee JH, Yang JE, Lim CS, Lee JA, Lee YS, Lee K, Kaang BK.

Mol Brain. 2016 May 23;9(1):56. doi: 10.1186/s13041-016-0222-6.

6.

Women with TSC: Relationship between Clinical, Lung Function and Radiological Features in a Genotyped Population Investigated for Lymphangioleiomyomatosis.

Di Marco F, Terraneo S, Imeri G, Palumbo G, La Briola F, Tresoldi S, Volpi A, Gualandri L, Ghelma F, Alfano RM, Montanari E, Gorio A, Lesma E, Peron A, Canevini MP, Centanni S.

PLoS One. 2016 May 12;11(5):e0155331. doi: 10.1371/journal.pone.0155331. eCollection 2016.

7.

Imaging Manifestations of a Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis.

Stein JR, Reidman DA.

Case Rep Radiol. 2016;2016:3750450. doi: 10.1155/2016/3750450. Epub 2016 Jan 31.

8.

Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.

Budde K, Zonnenberg BA, Frost M, Cheung W, Urva S, Brechenmacher T, Stein K, Chen D, Kingswood JC, Bissler JJ.

Br J Clin Pharmacol. 2016 May;81(5):958-70. doi: 10.1111/bcp.12834. Epub 2016 Mar 5.

9.

A Case of Tuberous Sclerosis Without Multiorgan Involvement.

Falsafi P, Taghavi-Zenouz A, Khorshidi-Khiyavi R, Nezami N, Estiar MA.

Glob J Health Sci. 2015 Feb 24;7(5):124-31. doi: 10.5539/gjhs.v7n5p124.

10.

TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex.

Kingswood JC, Bruzzi P, Curatolo P, de Vries PJ, Fladrowski C, Hertzberg C, Jansen AC, Jozwiak S, Nabbout R, Sauter M, Touraine R, O'Callaghan F, Zonnenberg B, Crippa S, Comis S, d'Augères GB, Belousova E, Carter T, Cottin V, Dahlin M, Ferreira JC, Macaya A, Benedik MP, Sander V, Youroukos S, Castellana R, Ulker B, Feucht M.

Orphanet J Rare Dis. 2014 Nov 26;9:182. doi: 10.1186/s13023-014-0182-9.

11.

Tuberous sclerosis complex: perioperative considerations.

Rabito MJ, Kaye AD.

Ochsner J. 2014 Summer;14(2):229-39. Review.

12.

The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.

Kingswood JC, Jozwiak S, Belousova ED, Frost MD, Kuperman RA, Bebin EM, Korf BR, Flamini JR, Kohrman MH, Sparagana SP, Wu JY, Brechenmacher T, Stein K, Berkowitz N, Bissler JJ, Franz DN.

Nephrol Dial Transplant. 2014 Jun;29(6):1203-10. doi: 10.1093/ndt/gfu013. Epub 2014 Apr 11.

13.

Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation.

Lasarge CL, Danzer SC.

Front Mol Neurosci. 2014 Mar 14;7:18. doi: 10.3389/fnmol.2014.00018. eCollection 2014. Review.

14.

Monoallelic germline TSC1 mutations are permissive for T lymphocyte development and homeostasis in tuberous sclerosis complex individuals.

Pilipow K, Basso V, Migone N, Mondino A.

PLoS One. 2014 Mar 14;9(3):e91952. doi: 10.1371/journal.pone.0091952. eCollection 2014.

16.

Reduced juvenile long-term depression in tuberous sclerosis complex is mitigated in adults by compensatory recruitment of mGluR5 and Erk signaling.

Potter WB, Basu T, O'Riordan KJ, Kirchner A, Rutecki P, Burger C, Roopra A.

PLoS Biol. 2013;11(8):e1001627. doi: 10.1371/journal.pbio.1001627. Epub 2013 Aug 13.

17.

Trends in the prevalence of tuberous sclerosis complex manifestations: an epidemiological study of 166 Japanese patients.

Wataya-Kaneda M, Tanaka M, Hamasaki T, Katayama I.

PLoS One. 2013 May 17;8(5):e63910. doi: 10.1371/journal.pone.0063910. Print 2013.

18.

Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).

Goncharova EA, Goncharov DA, Fehrenbach M, Khavin I, Ducka B, Hino O, Colby TV, Merrilees MJ, Haczku A, Albelda SM, Krymskaya VP.

Sci Transl Med. 2012 Oct 3;4(154):154ra134. doi: 10.1126/scitranslmed.3003840.

19.

Supernumerary centrosomes nucleate extra cilia and compromise primary cilium signaling.

Mahjoub MR, Stearns T.

Curr Biol. 2012 Sep 11;22(17):1628-34. doi: 10.1016/j.cub.2012.06.057. Epub 2012 Jul 26.

20.

Real-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complex.

Liu F, Lunsford EP, Tong J, Ashitate Y, Gibbs SL, Yu J, Choi HS, Henske EP, Frangioni JV.

PLoS One. 2012;7(6):e38589. doi: 10.1371/journal.pone.0038589. Epub 2012 Jun 15.

Supplemental Content

Support Center